|
1
|
Zhelev Z, Ohba H, Bakalova R, Hadjimitova
V, Ishikawa M, Shinohara Y and Baba Y: Phenothiazines suppress
proliferation and induce apoptosis in cultured leukemic cells
without any influence on the viability of normal lymphocytes.
Phenothiazines and leukemia. Cancer Chemother Pharmacol.
53:267–275. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Min KJ, Seo BR, Bae YC, Yoo YH and Kwon
TK: Antipsychotic agent thioridazine sensitizes renal carcinoma
Caki cells to TRAIL-induced apoptosis through reactive oxygen
species-mediated inhibition of Akt signaling and downregulation of
Mcl-1 and c-FLIP(L). Cell Death Dis. 5:e10632014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng HW, Liang YH, Kuo YL, Chuu CP, Lin
CY, Lee MH, Wu AT, Yeh CT, Chen EI, Whang-Peng J, et al:
Identification of thioridazine, an antipsychotic drug, as an
antiglioblastoma and anticancer stem cell agent using public gene
expression data. Cell Death Dis. 6:e17532015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cowap J and Hardy J: Thioridazine in the
management of cancer-related sweating. J Pain Symptom Manage.
15:2661998.PubMed/NCBI
|
|
5
|
Zhukovsky DS: Fever and sweats in the
patient with advanced cancer. Hematol Oncol Clin North Am.
16579–588. (viii)2002.viii. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ly KL, Chidgey J, Addington-Hall J and
Hotopf M: Depression in palliative care: A systematic review. Part
2. Treatment. Palliat Med. 16:279–284. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kang S, Dong SM, Kim BR, Park MS, Trink B,
Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the
PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
Apoptosis. 17:989–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rho SB, Kim BR and Kang S: A gene
signature-based approach identifies thioridazine as an inhibitor of
phosphatidylinositol-3-kinase (PI3K)/AKT pathway in ovarian cancer
cells. Gynecol Oncol. 120:121–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choi AR, Kim JH and Yoon S: Thioridazine
specifically sensitizes drug-resistant cancer cells through highly
increase in apoptosis and P-gp inhibition. Tumour Biol.
35:9831–9838. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu M, Li J, Luo Z, Zhang S, Xue S, Wang K,
Shi Y, Zhang C, Chen H and Li Z: Roles of dopamine receptors and
their antagonist thioridazine in hepatoma metastasis. Onco Targets
Ther. 8:1543–1552. 2015.PubMed/NCBI
|
|
11
|
Gong L, Wang Y, Tong S, Liu L, Niu L, Yuan
Y and Bao Y: Mechanism of killing effect of thioridazine on human
lung cancer PC9 cells. Zhongguo Fei Ai Za Zhi. 18:727–733. 2015.(In
Chinese). PubMed/NCBI
|
|
12
|
Yin T, He S, Shen G, Ye T, Guo F and Wang
Y: Dopamine receptor antagonist thioridazine inhibits tumor growth
in a murine breast cancer model. Mol Med Rep. 12:4103–4108.
2015.PubMed/NCBI
|
|
13
|
Meng Q, Sun X, Wang J and Wang Y:
Mechanism of thioridazine plus medroxyprogesterone in the treatment
of endometrial cancer. Zhonghua Yi Xue Za Zhi. 95:1540–1543.
2015.(In Chinese). PubMed/NCBI
|
|
14
|
Liu JK, Hao YJ, Huang JW, Li X, Cai HB and
Peng K: Mechanism of thioridazine-induced apoptosis of human
colorectal cancer SW480 cells. Nan Fang Yi Ke Da Xue Xue Bao.
35:511–515. 2015.(In Chinese). PubMed/NCBI
|
|
15
|
Sachlos E, Risueño RM, Laronde S,
Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn
A, Graham M, et al: Identification of drugs including a dopamine
receptor antagonist that selectively target cancer stem cells.
Cell. 149:1284–1297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ke XY, Lin Ng VW, Gao SJ, Tong YW, Hedrick
JL and Yang YY: Co-delivery of thioridazine and doxorubicin using
polymeric micelles for targeting both cancer cells and cancer stem
cells. Biomaterials. 35:1096–1108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dick JE: Looking ahead in cancer stem cell
research. Nat Biotechnol. 27:44–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guan Y, Gerhard B and Hogge DE: Detection,
isolation, and stimulation of quiescent primitive leukemic
progenitor cells from patients with acute myeloid leukemia (AML).
Blood. 101:3142–3149. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim EJ, Kang JI, Kwak JW, Jeon CH, Tung
NH, Kim YH, Choi CH, Hyun JW, Koh YS, Yoo ES, et al: The anticancer
effect of (1S,2S,3E,7E,11E)-3,7,11,
15-cembratetraen-17,2-olide(LS-1) through the activation of TGF-β
signaling in SNU-C5/5-FU, fluorouracil-resistant human colon cancer
cells. Mar Drugs. 13:1340–1359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang C, Tian Y, Song F, Fu C, Han B and
Wang Y: Salinomycin inhibits the growth of colorectal carcinoma by
targeting tumor stem cells. Oncol Rep. 34:2469–2476.
2015.PubMed/NCBI
|
|
22
|
Amaral L, Kristiansen JE, Abebe LS and
Millett W: Inhibition of the respiration of multi-drug resistant
clinical isolates of Mycobacterium tuberculosis by thioridazine:
Potential use for initial therapy of freshly diagnosed
tuberculosis. J Antimicrob Chemother. 38:1049–1053. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boeree MJ: Global clinical trials for the
treatment of TB with thioridazine. Recent Pat Antiinfect Drug
Discov. 6:99–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kleibel F: A method of alleviation of pain
in cancer patients. Clinical trial of thioridazine (Melleril and
Mellerettes) in 251 patients. Munch Med Wochenschr. 103:2341–2343.
1961.(In German). PubMed/NCBI
|
|
25
|
Smith RC, Baumgartner R, Burd A,
Ravichandran GK and Mauldin M: Haloperidol and thioridazine drug
levels and clinical response in schizophrenia: Comparison of
gas-liquid chromatography and radioreceptor drug level assays.
Psychopharmacol Bull. 21:52–58. 1985.PubMed/NCBI
|
|
26
|
Mu J, Xu H, Yang Y, Huang W, Xiao J, Li M,
Tan Z, Ding Q, Zhang L, Lu J, et al: Thioridazine, an antipsychotic
drug, elicits potent antitumor effects in gastric cancer. Oncol
Rep. 31:2107–2114. 2014.PubMed/NCBI
|
|
27
|
Tuynder M, Fiucci G, Prieur S, Lespagnol
A, Géant A, Beaucourt S, Duflaut D, Besse S, Susini L, Cavarelli J,
et al: Translationally controlled tumor protein is a target of
tumor reversion. Proc Natl Acad Sci USA. 101:15364–15369. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Basta-Kaim A, Budziszewska B, Jagła G,
Nowak W, Kubera M and Lasoń W: Inhibitory effect of antipsychotic
drugs on the Con A- and LPS-induced proliferative activity of mouse
splenocytes: A possible mechanism of action. J Physiol Pharmacol.
57:247–264. 2006.PubMed/NCBI
|
|
29
|
Park MS, Dong SM, Kim BR, Seo SH, Kang S,
Lee EJ, Lee SH and Rho SB: Thioridazine inhibits angiogenesis and
tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian
cancer xenografts. Oncotarget. 5:4929–4934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hercbergs A: Thioridazine: A radiation
enhancer in advanced cervical cancer? Lancet. 2:7371988. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gatto F and Hofland LJ: The role of
somatostatin and dopamine D2 receptors in endocrine tumors. Endocr
Relat Cancer. 18:R233–R251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Akiyama S, Shiraishi N, Kuratomi Y,
Nakagawa M and Kuwano M: Circumvention of multiple-drug resistance
in human cancer cells by thioridazine, trifluoperazine, and
chlorpromazine. J Natl Cancer Inst. 76:839–844. 1986.PubMed/NCBI
|
|
33
|
Efferth T and Volm M: Reversal of
doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of
different resistance mechanisms. Cancer Lett. 70:197–202. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sutton LP and Rushlow WJ: The dopamine D2
receptor regulates Akt and GSK-3 via Dvl-3. Int J
Neuropsychopharmacol. 15:965–979. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Castaing M, Loiseau A and Cornish-Bowden
A: Synergy between verapamil and other multidrug -resistance
modulators in model membranes. J Biosci. 32:737–746. 2007.
View Article : Google Scholar : PubMed/NCBI
|
